Drug Trial Radar · NCT03715205
Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)
Last checked: Nov 20, 2026Latest source record: Aug 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
150
Actual
Start
Jan 31, 2019
Primary completion
Aug 21, 2024
Study completion Aug 21, 2024
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Oct 23, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study has been designed to evaluate the safety of pembrolizumab in participants in India with unresectable or metastatic melanoma and participants with non-small cell lung cancer (NSCLC) who are either untreated (programmed cell death ligand 1 \[PD-L1\] ≥50%) or have experienced disease progression after a platinum-containing systemic therapy (PD-L1 ≥1%).
Conditions
- Carcinoma, Non-Small-Cell Lung
- Melanoma
Interventions
PembrolizumabDrug
Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With an Adverse Event (AE)Time frame: Up to approximately 66.5 months
- Number of Participants With a Serious Adverse Event (SAE)Time frame: Up to approximately 66.5 months
- Number of Participants With a Drug-Related AETime frame: Up to approximately 66.5 months
- Number of Participants With a Drug-Related SAETime frame: Up to approximately 66.5 months
- Number of Participants Who Discontinued Study Drug Due to an AETime frame: Up to approximately 26 months
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Rajiv Gandhi Cancer Institute and Research Centre ( Site 0003)
Delhi, India
Nizam's Institute of Medical Sciences ( Site 0011)
Hyderabad, Andhra Pradesh, India
Artemis Health Institute ( Site 0007)
Gurgaon, Haryana, India
Tata Memorial Hospital [M] ( Site 0005)
Mumbai, Maharashtra, India
Kokilaben Ben Dhirubhai Ambani Hosp & Med Res Inst. ( Site 0001)
Mumbai, Maharashtra, India
Deenanath Mangeshkar Hospital and Research Center ( Site 0009)
Pune, Maharashtra, India
All India Institute of Medical Sciences ( Site 0012)
New Delhi, National Capital Territory of Delhi, India
Indraprastha Apollo Hospitals ( Site 0008)
New Delhi, National Capital Territory of Delhi, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.